Advanced Hydrogels for Cell Therapy in Demyelinating Diseases
Programmable Hydrogels for Optimized Human Oligodendrocyte Transplantation in Demyelinating Disease
This work develops new materials to help transplanted cells survive and thrive, aiming to restore lost function in conditions like multiple sclerosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-11125894 on NIH RePORTER |
What this research studies
Many serious brain diseases, such as multiple sclerosis, damage the protective covering around nerve cells, making it hard for the brain to repair itself. While cell therapies offer hope to fix this damage and bring back neurological function, a big challenge is making sure the transplanted cells survive and work correctly. This project creates special gel materials that protect these cells during transplantation and help them grow into the right type of cells needed for repair. By improving cell survival, we hope to make these promising therapies more effective for patients.
Who could benefit from this research
Good fit: This foundational research is for patients with demyelinating diseases like multiple sclerosis who might benefit from future cell-based regenerative therapies.
Not a fit: Patients seeking immediate treatment options or those with conditions unrelated to demyelinating diseases may not directly benefit from this early-stage research.
Why it matters
Potential benefit: If successful, this work could lead to more effective cell therapies for demyelinating diseases, potentially restoring neurological function and improving quality of life for patients.
How similar studies have performed: While cell transplantation has shown promise, previous attempts have faced challenges with cell survival and integration, making this approach to improve cell delivery novel and critical.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Andreadis, Stelios T. — State University of New York at Buffalo
- Study coordinator: Andreadis, Stelios T.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.